title: Definitive chemoradiotherapy with carboplatin for squamous cell carcinoma of the head and neck.
abstract: Definitive concurrent chemoradiotherapy (CRT) is considered the standard of care for organ preservation and is the only potentially curative therapy for surgically unresectable patients with stage III to IVb locally advanced squamous cell carcinoma of the head and neck. In patients with high risks for adverse events utilizing cisplatin, carboplatin has been empirically substituted. The objective of this study was to estimate the locoregional control rate, progression-free survival, overall survival, and adverse events in locally advanced squamous cell carcinoma of the head and neck patients treated with CRT utilizing carboplatin.
  
  
  
  A retrospective single-arm analysis.
  
  
  
  Data on consecutive patients who fit the eligibility criteria were collected. Eligible patients were treated with 70 Gy of radiation therapy and at least two cycles of carboplatin (area of curve [AUC] of 5 between January 2007 to December 2013.
  
  
  
  Fifty-four patients were identified. Overall locoregional control rate was 50% (95% confidence interval [CI] 37%-63%). Median progression-free and overall survival were 21 (CI 11-33) and 40 (CI 33-NA) months, respectively. One-, 3-, and 5-year overall survival were 81% (CI 67%-89%), 59% (CI 41%-73%), and 42% (CI 22%-61%), respectively. Stage III/IVa patients (n = 45) had a median survival of 62 (CI 37-NA months) and 3 years of 71% (CI 53%-84%), whereas stage IVb (n = 9) had a median survival of 31 (CI 4-NA) months and none survived to 3 years.
  
  
  
  Definitive CRT with carboplatin for locally advanced squamous cell carcinoma of the head and neck was well tolerated and demonstrated comparable results to CRT with cisplatin.
  
  
  
  4. Laryngoscope, 127:2260-2264, 2017.
authors.affiliation: Department of Oncology, Barbara Ann Karmanos Cancer Institute/Wayne State University School of Medicine, Detroit, Michigan, U.S.A.
authors.forename: Misako
authors.initials: M
authors.lastname: Nagasaka
authors.affiliation: Division of Radiation Oncology, Department of Oncology, Barbara Ann Karmanos Cancer Institute/Wayne State University School of Medicine, Detroit, Michigan, U.S.A.
authors.forename: Mark
authors.initials: M
authors.lastname: Zaki
authors.affiliation: Department of Internal Medicine, Oakland University William Beaumont School of Medicine/Beaumont Health System, Detroit, Michigan, U.S.A.
authors.forename: Majd
authors.initials: M
authors.lastname: Issa
authors.affiliation: Division of Radiation Oncology, Department of Oncology, Barbara Ann Karmanos Cancer Institute/Wayne State University School of Medicine, Detroit, Michigan, U.S.A.
authors.forename: Harold
authors.initials: H
authors.lastname: Kim
authors.affiliation: Department of Oncology, Barbara Ann Karmanos Cancer Institute/Wayne State University School of Medicine, Detroit, Michigan, U.S.A.
authors.forename: Judith
authors.initials: J
authors.lastname: Abrams
authors.affiliation: Department of Oncology, Barbara Ann Karmanos Cancer Institute/Wayne State University School of Medicine, Detroit, Michigan, U.S.A.
authors.forename: Ammar
authors.initials: A
authors.lastname: Sukari
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D016190:Carboplatin / Q000008:administration & dosage*; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000628:therapy*; D059248:Chemoradiotherapy / Q000379:methods*; D002945:Cisplatin / Q000008:administration & dosage; D018572:Disease-Free Survival; D005260:Female; D006258:Head and Neck Neoplasms / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012189:Retrospective Studies; D000077195:Squamous Cell Carcinoma of Head and Neck; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D016190:Carboplatin; D002945:Cisplatin
keywords: Chemoradiotherapy; carboplatin; cisplatin; locally advanced squamous cell carcinoma of the head and neck; renal insufficiency